REDUCED FIELD-OF-VIEW DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH INVASIVE BREAST CANCER

FOV data acquired at MR1 and MR2. From MR1 to MR2, minimum tumor ADC decreased 29%, based on rFOV and increased 18%, based on standard FOV data. The change in tumor volume from MR1 to MR3 was classified as a non-response to taxanebased chemotherapy. Fig 1. rFOV and standard FOV imaging data for a patient with invasive breast cancer. The tumor (arrow) appears more heterogeneous with rFOV DWMRI. Both radiologists rated tumor depiction, heterogeneity, lesion conspicuity, and other qualitative features as superior on rFOV DW-MRI data as compared to standard. Quantitative analysis of the tumor ADC distribution showed that the minimum tumor ADC was lower with rFOV vs. standard FOV. REDUCED FIELD-OF-VIEW DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH INVASIVE BREAST CANCER